Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma IncfiledCriticalAventis Pharma Inc
Publication of PE20030562A1publicationCriticalpatent/PE20030562A1/en
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms
(AREA)
Abstract
SE REFIERE A UN COMPUESTO DE ACIDO (Z) -2-CIANO-3-HIDROXI-BUT-2-ENOICO-(4'-TRIFLUOROMETILFENIL)-AMIDA (TERIFLUNOMIDA) DE FORMULA I, SU ESTEREOISOMERO, UNA SAL FARMACEUTICAMENTE ACEPTABLE UTIL PARA EL TRATAMIENTO DE ESCLEROSIS MULTIPLE. EL COMPUESTO DE FORMULA I ES UN METABOLITO ACTIVO DE 5-METILISOXAZOL-4-CARBOXILICO-(4-TRIFLUOROMETIL)-ANILIDA (LEFLUNOMIDA)REFERS TO A COMPOUND OF (Z) -2-CYANE-3-HYDROXY-BUT-2-ENOIC- (4'-TRIFLUOROMETHYLPHENYL) -AMIDE (TERIFLUNOMIDE) OF FORMULA I, ITS STEREOISOMER, A PHARMACEUTICALLY ACCEPTABLE SALT MULTIPLE SCLEROSIS TREATMENT. THE COMPOUND OF FORMULA I IS AN ACTIVE METABOLITE OF 5-METHYLISOXAZOLE-4-CARBOXYL- (4-TRIFLUOROMETIL) -ANILIDE (LEFLUNOMIDE)
PE2002000280A2001-04-052002-04-05
A COMPOUND OF (Z) -2-CYANE-3-HYDROXY-BUT-2-ENOIC ACID- (4'-TRIFLUOROMETHYLPHENYL) -AMIDE
PE20030562A1
(en)
Novel diphenyl azetidinone with improved phzsiological characteristics, corresponding production method, medicaments containing said compound and use of the latter